Esperion Therapeutics, Inc. (ESPR) — Financial statements
Income statement, balance sheet, and cash flow for Esperion Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 403↑21.3% | 332↑185.7% | 116↑54.1% | 75↓3.8% | 78 | |
| Cost of Revenue | 129↑88.4% | 69↑58.6% | 43↑60.4% | 27↑89.7% | 14 | |
| Gross Profit | 274↑3.9% | 264↑260.9% | 73↑50.6% | 49↓24.5% | 64 | |
| Operating Expenses | ||||||
| R&D Expenses | 48↑3.5% | 46↓46.3% | 86↓27.6% | 119↑12.2% | 106 | |
| General & Administrative Expenses | 0.00↓100.0% | 138 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 26 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 166↑1.7% | 163↑14.4% | 143↑30.7% | 109↓41.0% | 185 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 214↑2.1% | 209↓8.4% | 229↑0.3% | 228↓21.6% | 291 | |
| Total Costs & Expenses | 343↑23.4% | 278↑2.2% | 272↑6.6% | 255↓16.4% | 305 | |
| Operating Results | ||||||
| Operating Income | 60↑10.8% | 54↑135.0% | -156↑13.3% | -180↑20.8% | -227 | |
| Depreciation & Amortization | 0.11↑66.7% | 0.06↓61.6% | 0.16↓67.2% | 0.50↓18.3% | 0.61 | |
| EBITDA | 60↑696.3% | 8↑105.0% | -150↑14.9% | -176↑20.6% | -222 | |
| EBIT | 60↑703.0% | 8↑105.0% | -150↑15.0% | -177↑20.6% | -223 | |
| Interest & Other Income | ||||||
| Net Interest Income | -81↓36.9% | -59↓0.5% | -59↓3.8% | -57↓22.6% | -46 | |
| Interest Income | 4 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 85↑42.8% | 59↑0.5% | 59↑3.8% | 57↑22.6% | 46 | |
| Non-Operating Income | 0.00↓100.0% | 47↑986.3% | -5↓99.5% | -3↑33.3% | -4 | |
| Other Income / Expenses | -81↑23.6% | -106↓97.7% | -54↑0.9% | -54↓27.8% | -42 | |
| Income Before Tax | -21↑59.7% | -52↑75.3% | -209↑10.4% | -234↑13.2% | -269 | |
| Income Tax Expense | 2 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -23↑56.2% | -52↑75.3% | -209↑10.4% | -234↑13.2% | -269 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -23↑56.2% | -52↑75.3% | -209↑10.4% | -234↑13.2% | -269 | |
| Bottom-Line Net Income | -23↑56.2% | -52↑75.3% | -209↑10.4% | -234↑13.2% | -269 | |
| EPS (Basic) | -0.11↑60.7% | -0.28↑86.2% | -2.03↑53.1% | -4.33↑60.7% | -11.03 | |
| EPS (Diluted) | -0.11↑60.7% | -0.28↑86.2% | -2.03↑53.1% | -4.33↑60.7% | -11.03 | |
| Weighted Average Shares | 208↑11.0% | 187↑81.5% | 103↑55.3% | 66↑129.8% | 29 | |
| Weighted Average Diluted Shares | 208↑11.0% | 187↑81.5% | 103↑55.3% | 66↑129.8% | 29 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.